Latest On T2 Biosystems, Inc (TTOO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 21:00 EST | News | T2 Biosystems up 31%, gets second largest order for sepsis-driven instrument | N/A |  |
| 2023-05-23 18:33 EST | News | T2 Biosystems GAAP EPS of -$1.32 misses by $0.07, revenue of $2.1M misses by $0.23M | N/A | |
| 2023-05-23 18:33 EST | News | T2 Biosystems files for FDA approval of T2Biothreat panel | N/A | |
| 2023-05-23 18:33 EST | News | T2 Biosystems sheds 28% on restructuring plans and Q1 miss | N/A | |
| 2023-05-23 18:33 EST | News | T2 Biosystems, Inc. (TTOO) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-03-24 01:25 EST | News | T2 Biosystems affirms plans to add Candida Auris fungus detection to test panel | N/A | |
| 2023-03-13 19:48 EST | News | T2 Biosystems GAAP EPS of -$1.41 beats by $0.92, revenue of $5.48M beats by $0.08M | N/A | |
| 2023-03-13 19:48 EST | News | T2 Biosystems, Inc. (TTOO) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-13 04:36 EST | News | T2 Biosystems Q4 2022 Earnings Preview | N/A | |
| 2023-02-15 16:36 EST | News | T2 Biosystems stock slides after pricing $12M securities offering | N/A | |
| 2023-02-14 01:24 EST | News | T2 Biosystems falls 5% on public offering | N/A | |
| 2023-01-24 20:11 EST | News | T2 Biosystems trades lower amid preliminary Q4 revenue results | N/A | |
| 2022-12-28 18:41 EST | News | T2 Biosystems innovative technology contract with Vizient extended | N/A | |
| 2022-11-11 00:13 EST | News | T2 Biosystems GAAP EPS of -$2.95 misses by $0.90, revenue of $3.68M misses by $1.05M | N/A | |
| 2022-11-11 00:13 EST | News | T2 Biosystems, Inc. (TTOO) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-10 06:41 EST | News | T2 Biosystems Q3 2022 Earnings Preview | N/A | |
| 2022-10-14 23:32 EST | News | T2 Biosystems rises 14% after multiple new studies show rapid disease detection | N/A | |
| 2022-10-13 17:39 EST | News | T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease | N/A | |
| 2022-10-12 10:52 EST | News | T2 Biosystems stock dips on revised annual guidance, executes reverse stock split | N/A | |
| 2022-09-29 16:29 EST | News | T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M | N/A | |
| 2022-09-23 00:23 EST | News | T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement | N/A | |
| 2022-08-27 03:47 EST | News | T2 Biosystems' Survival Riddle | N/A | |
| 2022-08-19 02:30 EST | News | T2 Biosystems (TTOO) Investor Presentation - Slideshow | N/A | |
| 2022-08-16 15:03 EST | News | T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-15 22:39 EST | News | T2 Biosystems GAAP EPS of -$0.10 misses by $0.01, revenue of $5.91M misses by $0.22M | N/A | |
| 2022-08-15 22:39 EST | News | T2 Biosystems Q2 results miss on top and bottom lines, but maintains 2022 outlook | N/A | |
| 2022-08-13 02:05 EST | News | T2 Biosystems Q2 2022 Earnings Preview | N/A | |
| 2022-08-10 06:34 EST | News | T2 Biosystems stock rises ~9% premarket on plans to develop diagnostic test for monkeypox | N/A | |
| 2022-07-11 09:12 EST | News | T2 Biosystems granted FDA Breakthrough Device Designation for Lyme disease test | N/A | |
| 2022-07-07 19:29 EST | News | T2 Biosystems cut to Neutral at BTIG on upcoming Q2 revenue miss, focus on cash burn | N/A | |
| 2022-07-06 11:49 EST | News | T2 Biosystems drops 4% on Q2 guidance and 2022 outlook | N/A | |
| 2022-06-07 03:08 EST | News | Inovio Pharma, Bionano Genomics among health care stocks to join Russell Microcap Index; Tonix Pharma, iBio to leave | N/A | |
| 2022-05-21 19:14 EST | News | T2 Biosystems stock rises after issuance of U.S. patent for direct detection of Lyme disease | N/A | |
| 2022-05-07 09:08 EST | News | T2 Biosystems stock falls 17% as Q1 net loss widens Y/Y | N/A | |
| 2022-05-06 08:54 EST | News | T2 Biosystems GAAP EPS of -$0.10 misses by $0.02, revenue of $7.23M beats by $0.53M | N/A | |
| 2022-05-06 08:54 EST | News | T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-05 11:34 EST | News | T2 Biosystems Q1 2022 Earnings Preview | N/A | |
| 2022-04-27 12:45 EST | News | T2 Biosystems applies for FDA Breakthrough Device designation for its T2Biothreat Panel | N/A | |
| 2022-03-31 19:48 EST | News | T2 Biosystems announces additional funding of $4.4M for BARDA contract | N/A | |
| 2022-03-08 02:57 EST | News | A Roadmap To T2 Biosystems Story | N/A | |
| 2022-02-18 02:41 EST | News | T2 Biosystems GAAP EPS of -$0.07 beats by $0.03, revenue of $6.98M beats by $1.58M | N/A | |
| 2022-02-18 02:40 EST | News | T2 Biosystems stock up 19% on earnings beat, 2022 outlook | N/A | |
| 2022-02-18 02:40 EST | News | T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-15 11:32 EST | News | T2 Biosystems amends term loan agreement with CRG | N/A | |
| 2022-02-03 18:34 EST | News | T2 Biosystems' test detects Omicron subvariants | N/A | |
| 2022-01-11 19:03 EST | News | T2 Biosystems sees Q4 revenue ahead of consensus | N/A | |
| 2022-01-04 19:17 EST | News | Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022 | N/A | |
| 2021-12-01 10:12 EST | News | T2 Biosystems' T2SARS-CoV-2 Panel detects Omicron variant | N/A | |
| 2021-11-05 14:36 EST | News | T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 17:39 EST | News | T2 Biosystems names Brett Giffin as chief commercial officer | N/A | |
About T2 Biosystems, Inc (TTOO):
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
General
- Name T2 Biosystems, Inc
- Symbol TTOO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Fiscal Year EndDecember
- IPO Date2014-08-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.t2biosystems.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 13.12
- Price/Book (Most Recent Quarter) 33.26
- Enterprise Value Revenue 16.76
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.29
- Next Year EPS Estimate -$0.24
- Next Quarter EPS Estimate -$0.07
- Profit Margin -258%
- Operating Margin -228%
- Return on Assets -48%
- Revenue 18.13 million
- Earnings Per Share -$1.28
- Revenue Per Share $0.15
- Gross Profit -20069000
- Quarterly Earnings Growth 153.8%
View More
Highlights
- Market Capitalization 266.54 million
- EBITDA -47715000
- PE Ratio -0.5
- Analyst Target Price $2.83
- Book Value Per Share $0.06
View More
Share Statistics
- Shares Outstanding 148.08 million
- Shares Float 140.6 million
- % Held by Insiders 481%
- % Held by Institutions 12.72%
- Shares Short 9.42 million
- Shares Short Prior Month 9.76 million
- Short Ratio 0.47
- Short % of Float 7%
- Short % of Shares Outstanding 6%
View More
Technicals
- Beta 0.49
- 52 Week High $3.79
- 52 Week Low $0.34
- 50 Day Moving Average 2.41
- 200 Day Moving Average 1.6
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
T2 Biosystems, Inc (TTOO) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
T2 Biosystems, Inc (TTOO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $N/A | -$0.07 | -$0.08 | 6.67% |
| 2020-09-30 | 2020-11-04 | $N/A | -$0.08 | -$0.08 | 3.96% |
| 2020-06-30 | 2020-08-11 | $N/A | -$0.09 | -$0.13 | 30.77% |
| 2020-03-31 | 2020-05-05 | $2.55 million | -$0.22 | -$0.24 | 8.33% |
| 2019-12-31 | 2020-02-24 | $3.07 million | -$0.30 | -$0.27 | -9.49% |
| 2019-09-30 | 2019-11-18 | $1.68 million | -$0.31 | -$0.32 | 2.36% |
| 2019-06-30 | 2019-07-30 | $1.8 million | -$0.35 | -$0.33 | -7.69% |
| 2019-03-31 | 2019-05-02 | $1.79 million | -$0.34 | -$0.31 | -8.97% |
| 2018-12-31 | 2019-03-07 | $1.79 million | -$0.35 | -$0.30 | -18.24% |
| 2018-09-30 | 2018-11-01 | $2.47 million | -$0.25 | -$0.33 | 24.7% |
| 2018-06-30 | 2018-08-02 | $3.93 million | -$0.32 | -$0.34 | 4.48% |
| 2018-03-31 | 2018-05-08 | $2.31 million | -$0.36 | -$0.38 | 4% |
| 2017-12-31 | 2018-03-19 | $1.66 million | -$0.51 | -$0.44 | -15.91% |
| 2017-09-30 | 2017-11-02 | $1.11 million | -$0.45 | -$0.49 | 7.22% |
| 2017-06-30 | 2017-08-03 | $956000 | -$0.50 | -$0.49 | -2.04% |
| 2017-03-31 | 2017-05-02 | $941000 | -$0.48 | -$0.43 | -10.78% |
| 2016-12-31 | 2017-03-15 | $909000 | -$0.48 | -$0.44 | -9.92% |
| 2016-09-30 | 2016-11-01 | $1.09 million | -$0.51 | -$0.53 | 3.41% |
| 2016-06-30 | 2016-08-01 | $990000 | -$0.58 | -$0.56 | -4.19% |
| 2016-03-31 | 2016-05-02 | $1.1 million | -$0.55 | -$0.54 | -1.31% |
| 2015-12-31 | 2016-02-16 | $1.01 million | -$0.56 | -$0.59 | 4.55% |
| 2015-09-30 | 2015-11-02 | $1.05 million | -$0.57 | -$0.59 | 3.39% |
| 2015-06-30 | 2015-08-04 | $565000 | -$0.54 | -$0.57 | 5.26% |
| 2015-03-31 | 2015-05-05 | $188000 | -$0.53 | -$0.57 | 7.02% |
| 2014-12-31 | 2015-02-17 | $119000 | -$0.45 | -$0.44 | -2.27% |
| 2014-09-30 | 2014-11-04 | $N/A | -$0.71 | -$0.57 | -24.56% |
| 2014-06-30 | 2014-09-19 | $N/A | -$6.35 | -$3.92 | -61.99% |
T2 Biosystems, Inc (TTOO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
T2 Biosystems, Inc (TTOO) Chart:
T2 Biosystems, Inc (TTOO) News:
Below you will find a list of latest news for T2 Biosystems, Inc (TTOO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
T2 Biosystems, Inc (TTOO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 0.5 | 0.1 | CALL | 224 | 595 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 1 | 0.05 | CALL | 34 | 173 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 1.5 | 0.06 | CALL | 5 | 6 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 0.5 | 0.1 | CALL | 76 | 367 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 1 | 0.05 | CALL | 205 | 1493 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 1.5 | 0.12 | CALL | 1 | 19 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 0.5 | 0.4 | PUT | 1 | 2 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 1.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 0.5 | 0.15 | CALL | 1095 | 6284 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 1 | 0.05 | CALL | 32 | 251 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 1.5 | 0.05 | CALL | 23 | 145 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 0.5 | 0.4 | PUT | 15 | 27 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 1.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
Latest TTOO Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 5:50 PM EST | 100 | $0.1701 |
| Jun 13, 2022 6:37 PM EST | 100 | $0.1701 |
| Jun 13, 2022 6:37 PM EST | 100 | $0.1701 |
| Jun 13, 2022 7:00 PM EST | 100 | $0.1701 |
| Jun 13, 2022 7:16 PM EST | 100 | $0.1701 |
T2 Biosystems, Inc (TTOO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520184030/0001193125-20-184030-index.htm |
| 2018-10-23 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1492674/000000000018033146/0000000000-18-033146-index.htm |
| 2018-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000076999318000385/0000769993-18-000385-index.htm |
| 2018-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000076999318000386/0000769993-18-000386-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000076999319000004/0000769993-19-000004-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1492674/000076999319000180/0000769993-19-000180-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000076999319000401/0000769993-19-000401-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000076999320000004/0000769993-20-000004-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000076999320000005/0000769993-20-000005-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1492674/000076999320000125/0000769993-20-000125-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1492674/000089542119000083/0000895421-19-000083-index.htm |
| 2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018681/0000899243-18-018681-index.htm |
| 2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018682/0000899243-18-018682-index.htm |
| 2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018683/0000899243-18-018683-index.htm |
| 2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018684/0000899243-18-018684-index.htm |
| 2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018686/0000899243-18-018686-index.htm |
| 2018-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318020503/0000899243-18-020503-index.htm |
| 2018-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318020506/0000899243-18-020506-index.htm |
| 2018-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318020507/0000899243-18-020507-index.htm |
| 2018-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318020508/0000899243-18-020508-index.htm |
| 2018-07-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318020510/0000899243-18-020510-index.htm |
| 2018-09-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024446/0000899243-18-024446-index.htm |
| 2018-09-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2018-09-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318025002/0000899243-18-025002-index.htm |
| 2018-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924318028518/0000899243-18-028518-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319000293/0000899243-19-000293-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319000294/0000899243-19-000294-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002638/0000899243-19-002638-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002639/0000899243-19-002639-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002640/0000899243-19-002640-index.htm |
| 2019-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003306/0000899243-19-003306-index.htm |
| 2019-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003310/0000899243-19-003310-index.htm |
| 2019-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003312/0000899243-19-003312-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319004672/0000899243-19-004672-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319004673/0000899243-19-004673-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319004674/0000899243-19-004674-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319004675/0000899243-19-004675-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319004676/0000899243-19-004676-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016441/0000899243-19-016441-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016448/0000899243-19-016448-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016450/0000899243-19-016450-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016456/0000899243-19-016456-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016463/0000899243-19-016463-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016819/0000899243-19-016819-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016821/0000899243-19-016821-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016822/0000899243-19-016822-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016823/0000899243-19-016823-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319023459/0000899243-19-023459-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319023461/0000899243-19-023461-index.htm |
| 2019-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319023465/0000899243-19-023465-index.htm |
| 2019-09-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924319023537/0000899243-19-023537-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000182/0000899243-20-000182-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000185/0000899243-20-000185-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000700/0000899243-20-000700-index.htm |
| 2020-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000995/0000899243-20-000995-index.htm |
| 2020-01-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320001149/0000899243-20-001149-index.htm |
| 2020-01-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320002026/0000899243-20-002026-index.htm |
| 2020-01-29 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320002271/0000899243-20-002271-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320003298/0000899243-20-003298-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320003299/0000899243-20-003299-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320003302/0000899243-20-003302-index.htm |
| 2020-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320004327/0000899243-20-004327-index.htm |
| 2020-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320004332/0000899243-20-004332-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005805/0000899243-20-005805-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005806/0000899243-20-005806-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005808/0000899243-20-005808-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320006668/0000899243-20-006668-index.htm |
| 2020-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320008865/0000899243-20-008865-index.htm |
| 2020-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320008866/0000899243-20-008866-index.htm |
| 2020-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320008867/0000899243-20-008867-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320009493/0000899243-20-009493-index.htm |
| 2020-06-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320017342/0000899243-20-017342-index.htm |
| 2020-06-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320017343/0000899243-20-017343-index.htm |
| 2020-06-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320017344/0000899243-20-017344-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320021769/0000899243-20-021769-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320021791/0000899243-20-021791-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320021793/0000899243-20-021793-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000089924320021797/0000899243-20-021797-index.htm |
| 2019-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1492674/000090266419000746/0000902664-19-000746-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1492674/000090266420000826/0000902664-20-000826-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1492674/000090571819000223/0000905718-19-000223-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1492674/000091957419001448/0000919574-19-001448-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000095012320007901/0000950123-20-007901-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000095012320007909/0000950123-20-007909-index.htm |
| 2020-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1492674/000095012320007914/0000950123-20-007914-index.htm |
| 2018-06-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312518191616/0001193125-18-191616-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312518240713/0001193125-18-240713-index.htm |
| 2018-09-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312518269105/0001193125-18-269105-index.htm |
| 2018-10-15 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1492674/000119312518299340/0001193125-18-299340-index.htm |
| 2018-10-15 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1492674/000119312518299347/0001193125-18-299347-index.htm |
| 2018-10-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1492674/000119312518304192/0001193125-18-304192-index.htm |
| 2018-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312518319301/0001193125-18-319301-index.htm |
| 2018-12-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312518347488/0001193125-18-347488-index.htm |
| 2019-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1492674/000119312519040752/0001193125-19-040752-index.htm |
| 2019-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519072865/0001193125-19-072865-index.htm |
| 2019-03-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519081936/0001193125-19-081936-index.htm |
| 2019-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1492674/000119312519122530/0001193125-19-122530-index.htm |
| 2019-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1492674/000119312519122542/0001193125-19-122542-index.htm |
| 2019-04-30 | DEFR14A | Revised definitive proxy soliciting materials | https://www.sec.gov/Archives/edgar/data/1492674/000119312519129234/0001193125-19-129234-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519140936/0001193125-19-140936-index.htm |
| 2019-05-31 | SD | https://www.sec.gov/Archives/edgar/data/1492674/000119312519162569/0001193125-19-162569-index.htm | |
| 2019-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519170912/0001193125-19-170912-index.htm |
| 2019-07-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1492674/000119312519207002/0001193125-19-207002-index.htm |
| 2019-07-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1492674/000119312519207011/0001193125-19-207011-index.htm |
| 2019-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519207110/0001193125-19-207110-index.htm |
| 2019-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519210939/0001193125-19-210939-index.htm |
| 2019-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519241968/0001193125-19-241968-index.htm |
| 2019-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519242066/0001193125-19-242066-index.htm |
| 2019-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519290892/0001193125-19-290892-index.htm |
| 2019-11-13 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1492674/000119312519291010/0001193125-19-291010-index.htm |
| 2019-11-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312519296088/0001193125-19-296088-index.htm |
| 2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520004752/0001193125-20-004752-index.htm |
| 2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520004754/0001193125-20-004754-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520051831/0001193125-20-051831-index.htm |
| 2020-03-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1492674/000119312520067410/0001193125-20-067410-index.htm |
| 2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520067413/0001193125-20-067413-index.htm |
| 2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520084070/0001193125-20-084070-index.htm |
| 2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520084288/0001193125-20-084288-index.htm |
| 2020-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520101433/0001193125-20-101433-index.htm |
| 2020-04-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1492674/000119312520101443/0001193125-20-101443-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520137518/0001193125-20-137518-index.htm |
| 2020-05-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520149358/0001193125-20-149358-index.htm |
| 2020-05-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1492674/000119312520153099/0001193125-20-153099-index.htm |
| 2020-05-29 | SD | https://www.sec.gov/Archives/edgar/data/1492674/000119312520155663/0001193125-20-155663-index.htm | |
| 2020-06-15 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1492674/000119312520169315/0001193125-20-169315-index.htm |
| 2020-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520169351/0001193125-20-169351-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520170945/0001193125-20-170945-index.htm |
| 2020-06-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1492674/000119312520180893/0001193125-20-180893-index.htm |
| 2020-06-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1492674/000119312520180906/0001193125-20-180906-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520184030/0001193125-20-184030-index.htm |
| 2020-07-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520192314/0001193125-20-192314-index.htm |
| 2020-08-05 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1492674/000119312520210044/0001193125-20-210044-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520213399/0001193125-20-213399-index.htm |
| 2020-08-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520221875/0001193125-20-221875-index.htm |
| 2020-09-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520259187/0001193125-20-259187-index.htm |
| 2020-10-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520275430/0001193125-20-275430-index.htm |
| 2020-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1492674/000119312520287709/0001193125-20-287709-index.htm |
| 2018-08-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459018018960/0001564590-18-018960-index.htm |
| 2018-11-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459018026265/0001564590-18-026265-index.htm |
| 2019-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1492674/000156459019007862/0001564590-19-007862-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459019018534/0001564590-19-018534-index.htm |
| 2019-08-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459019028440/0001564590-19-028440-index.htm |
| 2019-11-18 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459019043775/0001564590-19-043775-index.htm |
| 2019-11-20 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459019043898/0001564590-19-043898-index.htm |
| 2020-03-16 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1492674/000156459020011217/0001564590-20-011217-index.htm |
| 2020-04-29 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1492674/000156459020019519/0001564590-20-019519-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459020024073/0001564590-20-024073-index.htm |
| 2020-08-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459020039633/0001564590-20-039633-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1492674/000156459020051270/0001564590-20-051270-index.htm |
| 2018-10-24 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1492674/999999999518002710/9999999995-18-002710-index.htm |
| 2018-10-16 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1492674/999999999718008638/9999999997-18-008638-index.htm |
| 2019-09-06 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1492674/999999999719006730/9999999997-19-006730-index.htm |
| 2019-09-12 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1492674/999999999719006813/9999999997-19-006813-index.htm |
| 2020-02-06 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1492674/999999999720000571/9999999997-20-000571-index.htm |
| 2020-02-28 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1492674/999999999720001069/9999999997-20-001069-index.htm |
T2 Biosystems, Inc (TTOO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of T2 Biosystems, Inc (TTOO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 481%Institutional Ownership: 1272%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-09-18 | Thomas J. Lowery | Chief Scientific Officer | Buy | 29,411.00 | 1.96 | 57,645.56 | 105,872.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2018-09-18 | Thomas J. Lowery | Chief Scientific Officer | Sell | 14,647.00 | 6.14 | 89,932.58 | 128,821.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2018-09-18 | Thomas J. Lowery | Chief Scientific Officer | Buy | 36,235.00 | 2.45 | 88,775.75 | 142,107.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2018-09-18 | Thomas J. Lowery | Chief Scientific Officer | Buy | 1,361.00 | 2.25 | 3,062.25 | 143,468.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2018-06-28 | John M Sprague | Chief Financial Officer | Buy | 17,292.00 | 17,292.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018683/0000899243-18-018683-index.htm | ||
| 2019-06-11 | Michael J. Cima | Director | Sell | 3,240.00 | 1.43 | 4,633.20 | 213,178.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016823/0000899243-19-016823-index.htm |
| 2019-06-08 | Michael J. Cima | Director | Buy | 9,000.00 | 216,418.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016441/0000899243-19-016441-index.htm | ||
| 2020-02-24 | John M Sprague | Chief Financial Officer | Sell | 4,166.00 | 0.82 | 3,416.12 | 22,222.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320006668/0000899243-20-006668-index.htm |
| 2019-06-11 | JOHN W CUMMING | Director | Sell | 3,420.00 | 1.43 | 4,890.60 | 23,580.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016821/0000899243-19-016821-index.htm |
| 2020-02-21 | John M Sprague | Chief Financial Officer | Buy | 10,000.00 | 26,388.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320006668/0000899243-20-006668-index.htm | ||
| 2019-06-08 | JOHN W CUMMING | Director | Buy | 9,000.00 | 27,000.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016450/0000899243-19-016450-index.htm | ||
| 2019-01-01 | SEYMOUR LIEBMAN | Director | Buy | 9,708.00 | 27,708.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319000294/0000899243-19-000294-index.htm | ||
| 2018-06-28 | Alec Barclay | Officer | Buy | 24,086.00 | 34,979.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018684/0000899243-18-018684-index.htm | ||
| 2019-06-08 | SEYMOUR LIEBMAN | Director | Buy | 9,000.00 | 36,708.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016448/0000899243-19-016448-index.htm | ||
| 2018-09-11 | Alec Barclay | SVP, Operations | Buy | 10,000.00 | 37,155.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024446/0000899243-18-024446-index.htm | ||
| 2018-06-28 | John McDonough | President and CEO | Buy | 108,696.00 | 393,909.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018681/0000899243-18-018681-index.htm | ||
| 2017-11-30 | John McDonough | President & CEO | Buy | 47,423.00 | 406,604.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002639/0000899243-19-002639-index.htm | ||
| 2019-09-11 | Alec Barclay | SVP, Operations | Sell | 4,210.00 | 2.92 | 12,293.20 | 42,102.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319023537/0000899243-19-023537-index.htm |
| 2018-06-08-04:00 | Adrian M Jones | Director | Buy | 9,000.00 | 4,224,894.00 | https://www.sec.gov/Archives/edgar/data/1492674/000076999318000386/0000769993-18-000386-index.htm | ||
| 2018-06-08-04:00 | GOLDMAN SACHS GROUP INC | 10% Share Holder | Buy | 9,000.00 | 4,224,894.00 | https://www.sec.gov/Archives/edgar/data/1492674/000076999318000385/0000769993-18-000385-index.htm | ||
| 2019-01-01-05:00 | Adrian M Jones | Director | Buy | 13,289.00 | 4,236,453.00 | https://www.sec.gov/Archives/edgar/data/1492674/000076999319000004/0000769993-19-000004-index.htm | ||
| 2020-01-02-05:00 | Adrian M Jones | Director | Buy | 34,188.00 | 4,270,641.00 | https://www.sec.gov/Archives/edgar/data/1492674/000076999320000004/0000769993-20-000004-index.htm | ||
| 2020-01-02-05:00 | GOLDMAN SACHS GROUP INC | 10% Share Holder | Buy | 34,188.00 | 4,270,641.00 | https://www.sec.gov/Archives/edgar/data/1492674/000076999320000005/0000769993-20-000005-index.htm | ||
| 2018-09-18 | Thomas J. Lowery | Chief Scientific Officer | Sell | 85,595.00 | 6.17 | 528,121.15 | 43,226.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2018-09-19 | Thomas J. Lowery | Chief Scientific Officer | Sell | 37,902.00 | 6.20 | 234,992.40 | 43,226.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2018-09-20 | Thomas J. Lowery | Chief Scientific Officer | Sell | 48,205.00 | 6.18 | 297,906.90 | 43,226.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318025002/0000899243-18-025002-index.htm |
| 2019-02-01 | John McDonough | President & CEO | Sell | 9,443.00 | 3.47 | 32,767.21 | 439,688.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002639/0000899243-19-002639-index.htm |
| 2019-02-11 | John McDonough | President & CEO | Sell | 8,134.00 | 3.36 | 27,330.24 | 448,220.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003306/0000899243-19-003306-index.htm |
| 2019-01-31 | John McDonough | President & CEO | Sell | 4,895.00 | 3.35 | 16,398.25 | 449,131.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002639/0000899243-19-002639-index.htm |
| 2018-11-30 | John McDonough | President & CEO | Buy | 47,422.00 | 454,026.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002639/0000899243-19-002639-index.htm | ||
| 2019-02-09 | John McDonough | President & CEO | Buy | 16,666.00 | 456,354.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003306/0000899243-19-003306-index.htm | ||
| 2020-02-24 | Alec Barclay | SVP, Operations | Sell | 5,808.00 | 0.82 | 4,762.56 | 46,294.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005808/0000899243-20-005808-index.htm |
| 2019-09-11 | Alec Barclay | SVP, Operations | Buy | 10,000.00 | 46,312.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319023537/0000899243-19-023537-index.htm | ||
| 2020-01-08 | John McDonough | Director | Buy | 16,666.00 | 470,285.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000995/0000899243-20-000995-index.htm | ||
| 2020-02-03 | John McDonough | Director | Sell | 23,754.00 | 0.88 | 20,903.52 | 489,114.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320003299/0000899243-20-003299-index.htm |
| 2020-01-01 | SEYMOUR LIEBMAN | Director | Buy | 13,289.00 | 50.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000185/0000899243-20-000185-index.htm | ||
| 2017-11-30 | Michael Terrence Gibbs | General Counsel | Buy | 6,500.00 | 50,687.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002640/0000899243-19-002640-index.htm | ||
| 2018-06-28 | Michael Terrence Gibbs | General Counsel | Buy | 24,086.00 | 50,791.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018686/0000899243-18-018686-index.htm | ||
| 2020-01-23 | John McDonough | Director | Sell | 57,417.00 | 1.15 | 66,029.55 | 512,868.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320002026/0000899243-20-002026-index.htm |
| 2018-06-28 | Thomas J. Lowery | Chief Scientific Officer | Buy | 26,847.00 | 51,947.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318018682/0000899243-18-018682-index.htm | ||
| 2020-02-21 | Alec Barclay | SVP, Operations | Buy | 10,000.00 | 52,102.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005808/0000899243-20-005808-index.htm | ||
| 2018-11-06 | Stanley Lapidus | Director | Sell | 6,048.00 | 5.29 | 31,993.92 | 53,010.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318028518/0000899243-18-028518-index.htm |
| 2019-06-11 | Stanley Lapidus | Director | Sell | 9,000.00 | 1.44 | 12,960.00 | 53,010.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016822/0000899243-19-016822-index.htm |
| 2018-09-19 | Thomas J. Lowery | Chief Scientific Officer | Buy | 10,403.00 | 2.25 | 23,406.75 | 53,629.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2020-02-03 | Michael Terrence Gibbs | General Counsel | Sell | 3,283.00 | 0.88 | 2,889.04 | 53,954.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320003302/0000899243-20-003302-index.htm |
| 2019-02-01 | Michael Terrence Gibbs | General Counsel | Sell | 1,820.00 | 3.47 | 6,315.40 | 54,428.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002640/0000899243-19-002640-index.htm |
| 2019-01-31 | Michael Terrence Gibbs | General Counsel | Sell | 939.00 | 3.35 | 3,145.65 | 56,248.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002640/0000899243-19-002640-index.htm |
| 2020-02-11 | Michael Terrence Gibbs | General Counsel | Sell | 3,200.00 | 0.77 | 2,464.00 | 56,587.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320004327/0000899243-20-004327-index.htm |
| 2020-01-08 | John McDonough | Director | Buy | 100,000.00 | 570,285.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000995/0000899243-20-000995-index.htm | ||
| 2018-11-30 | Michael Terrence Gibbs | General Counsel | Buy | 6,500.00 | 57,187.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002640/0000899243-19-002640-index.htm | ||
| 2019-02-11 | Michael Terrence Gibbs | General Counsel | Sell | 3,005.00 | 3.36 | 10,096.80 | 57,237.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003310/0000899243-19-003310-index.htm |
| 2018-09-18 | Thomas J. Lowery | Chief Scientific Officer | Buy | 14,647.00 | 1.16 | 16,990.52 | 57,873.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2017-11-30 | Thomas J. Lowery | Chief Scientific Officer | Buy | 15,000.00 | 58,226.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002638/0000899243-19-002638-index.htm | ||
| 2018-11-06 | Stanley Lapidus | Director | Buy | 27,058.00 | 1.16 | 31,387.28 | 59,058.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318028518/0000899243-18-028518-index.htm |
| 2020-02-09 | Michael Terrence Gibbs | General Counsel | Buy | 5,833.00 | 59,787.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320004327/0000899243-20-004327-index.htm | ||
| 2019-02-09 | Michael Terrence Gibbs | General Counsel | Buy | 5,834.00 | 60,262.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003310/0000899243-19-003310-index.htm | ||
| 2020-02-24 | Michael Terrence Gibbs | General Counsel | Sell | 5,808.00 | 0.82 | 4,762.56 | 60,779.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005806/0000899243-20-005806-index.htm |
| 2019-06-08 | Stanley Lapidus | Director | Buy | 9,000.00 | 62,010.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016463/0000899243-19-016463-index.htm | ||
| 2020-02-03 | Thomas J. Lowery | Chief Scientific Officer | Sell | 7,535.00 | 0.88 | 6,630.80 | 62,169.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320003298/0000899243-20-003298-index.htm |
| 2020-02-11 | Thomas J. Lowery | Chief Scientific Officer | Sell | 3,200.00 | 0.77 | 2,464.00 | 64,802.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320004332/0000899243-20-004332-index.htm |
| 2020-02-21 | Michael Terrence Gibbs | General Counsel | Buy | 10,000.00 | 66,587.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005806/0000899243-20-005806-index.htm | ||
| 2019-02-01 | Thomas J. Lowery | Chief Scientific Officer | Sell | 4,185.00 | 3.47 | 14,521.95 | 66,875.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002638/0000899243-19-002638-index.htm |
| 2020-02-09 | Thomas J. Lowery | Chief Scientific Officer | Buy | 5,833.00 | 68,002.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320004332/0000899243-20-004332-index.htm | ||
| 2020-02-24 | Thomas J. Lowery | Chief Scientific Officer | Sell | 5,808.00 | 0.82 | 4,762.56 | 68,994.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005805/0000899243-20-005805-index.htm |
| 2019-02-11 | Thomas J. Lowery | Chief Scientific Officer | Sell | 3,005.00 | 3.36 | 10,096.80 | 69,704.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003312/0000899243-19-003312-index.htm |
| 2019-01-31 | Thomas J. Lowery | Chief Scientific Officer | Sell | 2,166.00 | 3.35 | 7,256.10 | 71,060.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002638/0000899243-19-002638-index.htm |
| 2019-02-09 | Thomas J. Lowery | Chief Scientific Officer | Buy | 5,834.00 | 72,709.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319003312/0000899243-19-003312-index.htm | ||
| 2018-11-30 | Thomas J. Lowery | Chief Scientific Officer | Buy | 15,000.00 | 73,226.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319002638/0000899243-19-002638-index.htm | ||
| 2020-02-21 | Thomas J. Lowery | Chief Scientific Officer | Buy | 10,000.00 | 74,802.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320005805/0000899243-20-005805-index.htm | ||
| 2018-09-20 | Thomas J. Lowery | Chief Scientific Officer | Buy | 31,603.00 | 3.22 | 101,761.66 | 74,829.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318025002/0000899243-18-025002-index.htm |
| 2018-09-18 | Thomas J. Lowery | Chief Scientific Officer | Buy | 18,588.00 | 1.31 | 24,350.28 | 76,461.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2019-01-01 | David B Elsbree | Director | Buy | 9,708.00 | 77,708.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319000293/0000899243-19-000293-index.htm | ||
| 2018-09-19 | Thomas J. Lowery | Chief Scientific Officer | Buy | 27,499.00 | 3.22 | 88,546.78 | 81,128.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318024949/0000899243-18-024949-index.htm |
| 2019-06-11 | David B Elsbree | Director | Sell | 3,600.00 | 1.44 | 5,184.00 | 83,108.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016819/0000899243-19-016819-index.htm |
| 2019-06-08 | David B Elsbree | Director | Buy | 9,000.00 | 86,708.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924319016456/0000899243-19-016456-index.htm | ||
| 2020-01-03 | David B Elsbree | Director | Sell | 5,316.00 | 1.16 | 6,166.56 | 91,081.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000700/0000899243-20-000700-index.htm |
| 2018-09-20 | Thomas J. Lowery | Chief Scientific Officer | Buy | 16,602.00 | 3.22 | 53,458.44 | 91,431.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924318025002/0000899243-18-025002-index.htm |
| 2020-01-01 | David B Elsbree | Director | Buy | 13,289.00 | 96,397.00 | https://www.sec.gov/Archives/edgar/data/1492674/000089924320000182/0000899243-20-000182-index.htm |